Interferon beta-1a in primary progressive multiple sclerosis

• Published in: Journal of the neurological sciences Vol. 206; no. 2; pp. 215 - 216
• Main Authors: Leary, Siobhan M, Thompson, Alan J
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Shannon Elsevier B.V 15.02.2003; Elsevier Science
• Subjects: Adjuvants, Immunologic - therapeutic use; Adolescent; Adult; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta - therapeutic use; Magnetic Resonance Imaging; Medical sciences; Middle Aged; Mitoxantrone - therapeutic use; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Multiple Sclerosis, Chronic Progressive - drug therapy; Neurology; Neuroprotective Agents - therapeutic use; Peptides - therapeutic use; Primary progressive multiple sclerosis; Riluzole - therapeutic use; Therapeutics; Treatment Outcome; Interferon beta-1a; Primary progressive multiple sclerosis; Therapeutics; Human; Nervous system diseases; Multiple sclerosis; Secondary; Inflammatory disease; Immunomodulator; Progressive; Chemotherapy; Randomization; Treatment; Central nervous system disease; Double blind study; Adult; Evolution
• ISSN: 0022-510X; 1878-5883
• DOI: 10.1016/S0022-510X(02)00350-7

There is currently no disease-modifying treatment proven to be of efficacy in primary progressive multiple sclerosis (PPMS). However, a number of therapeutic trials have recently been specifically designed for this group. These include a randomised controlled trial of interferon beta-1a which is discussed here. It is hoped that therapeutics in primary progressive multiple sclerosis will continue to expand and effective therapeutic agents will be developed.